Established name sizing in detailed running-text columns, incl. larger-type proviso

AI-verifiedblockerBinding lawRaised as a question — a person decides

Rule

For a prescription-drug print advertisement, if a column of running text contains detailed information on composition, prescribing, side effects, or contraindications and uses the proprietary name without that name being featured above or below the column, the established name must appear at least once in that column, in association with the proprietary name, at the same type size used in the column. However, where the proprietary name is used in that column in larger-size type than the type used in that column of running text, this same-size requirement is replaced by a half-as-large requirement: the established name must instead appear at least once, in association with the proprietary name, in type at least half as large as the type used for the most prominent presentation of the proprietary name in that column.

Check

Locate any column of running text containing detailed information as to composition, prescribing, side effects, or contraindications in which the proprietary name or designation is used and is not featured above or below the column. Confirm the established name appears at least once in that column in association with the proprietary name, at the same type size used in the column — or, if the proprietary name appears in that column in larger type than the type used in that column of running text, at type at least half as large as the most prominent presentation of the proprietary name in that column.

Escalate when

Escalate when it is unclear whether the proprietary name is "featured" above or below the column (which would make this in-column provision inapplicable), when it is unclear which presentation of the proprietary name in the column is the "most prominent" for benchmarking the half-as-large proviso, or when type sizes are close enough that reasonable reviewers could disagree whether the proprietary name's type is "larger" than the column's running-text type (triggering the proviso) or whether the established name meets the same-size or half-as-large threshold.

Where this comes from

21 CFR 202.1(b)(1). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…th, and in type at least half as large as the type used for, the most prominent presentation of the proprietary name or designation in such running text. If any advertisement includes a column with running text containing detailed information as to composition, prescribing, side effects, or contraindications and the proprietary name or designation is used in such column but is not featured above or below the column, the established name shall be used at least once in such column of running text in association with such proprietary name or designation and in the same type size used in such column of running text: Provided, however, That if the proprietary name or designation is used in such column of running text in larger size type, the established name shall be used at least once in association with, and in type at least half as large as the type used for, the most prominent presentation of the proprietary name or designation in such column of running text. Where the established name is required to accompany or to be used in association with the proprietary name or designation, the established name shall be placed in direct conjunction with the proprietary name or designation, and the relationship between the proprietary name or designation and the established name shall be made clear by use of a phrase such as “brand of” preceding the established name, by brackets sur…

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

Mediumprint

Drug classprescription

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is the operative third sentence of 21 CFR 202.1(b)(1), a mandatory 'shall' obligation, and the rule's trigger conditions (detailed-information column; proprietary name used in the column; not featured above or below the column) all appear verbatim in the source.
- Overstated: the source sentence is immediately qualified by a proviso — if the proprietary name is used in the column in larger size type, the established name need only be 'in type at least half as large as the type used for, the most prominent presentation' of the proprietary name in that column. The rule states an unqualified 'matching type size' requirement and would therefore flag compliant advertisements.
- Determinism wrong: whether the proprietary name is 'featured above or below the column' is a display/impression characterization, not a literal match, and once the proviso is included the standard turns expressly on 'the most prominent presentation' of the proprietary name. Presence of the established name alone does not settle the rule as scoped.
- Authority correct: 21 CFR 202.1 is a codified regulation, so 'binding' is right; locator 21 CFR 202.1(b)(1) is accurate.
- applies_when partially justified but missing an express limit: 'print' is reasonable given the column/type-size framing, but §202.1 opens by limiting itself to prescription drugs as defined in section 503(b)(1) FD&C Act / §201.105, and the rule carries no drug-class restriction.
- Severity defensible: failure to use the established name as required implicates section 502(n) misbranding, so 'blocker' is within range.
- Atomic: the presence requirement and its accompanying type-size condition are a single regulatory obligation in one sentence, not independently imposed requirements.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is the operative command in the third sentence of 21 CFR 202.1(b)(1), not an example, definition, or description of what is not required. The rule's trigger (column of running text with detailed information as to composition, prescribing, side effects, or contraindications; proprietary name used in the column but not featured above or below it) is taken verbatim from the preceding clause of the same sentence.
- applies_when is justified and appropriately limited: the section governs prescription-drug advertisements, and the column/type-size mechanics are inherently print. The rule correctly keeps this column-specific provision separate from the second sentence's page-level running-text provision, which has a different trigger.
- authority 'binding' is correct (codified regulation); locator 21 CFR 202.1(b)(1) is where the quoted sentence appears; 'blocker' is defensible because an established-name failure under 202.1(b) bears on misbranding of the advertisement.
- determinism 'judgment' is correct: the provision turns on whether the proprietary name is 'featured' above or below the column and on identifying the 'most prominent presentation' within the column, neither of which is settled by presence/absence or literal match.
- atomic: the same-size requirement and the half-as-large proviso are mutually exclusive branches of a single obligation, not independently checkable requirements; the proviso cannot stand alone.
- Defect: the rule statement glosses the proviso's trigger as the proprietary name being in 'larger-size type than the established name.' The source says only 'in larger size type,' whose contextual referent is the type size used in that column of running text (the baseline set by the immediately preceding clause). The interpolated comparator could route a compliant-size proprietary name into the more permissive half-as-large branch whenever the established name is undersized, inverting the check.
- Internal inconsistency: the Check text states the trigger faithfully ('if the proprietary name appears in larger type in the column'), while the Rule statement states it with the added 'than the established name' comparator, so the two disagree on when the proviso applies.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quoted clause is the operative third sentence of 21 CFR 202.1(b)(1), and the rule reproduces both its trigger ('If any advertisement includes a column with running text containing detailed information as to composition, prescribing, side effects, or contraindications and the proprietary name or designation is used in such column but is not featured above or below the column') and its consequence (established name at least once in the column, in association, same type size; or half-as-large where the proprietary name appears in larger type). This is regulatory text imposing a 'shall' obligation, not an example, definition, or preamble commentary.
- Not overstated: 'shall' is rendered as 'must'; the rule correctly preserves the limiting conditions — it applies only to a column of detailed running text, only where the proprietary name is used but NOT featured above or below the column, and it does not extend the column provision to the separate general running-text sentence or to the 'featured' accompaniment requirement earlier in (b)(1). The proviso is stated as replacing (not supplementing) the same-size standard, matching 'Provided, however'.
- Atomic: the same-size standard and the half-as-large proviso are mutually exclusive branches of a single obligation (established name type size in the column), selected by one condition; a reviewer applies exactly one branch per instance. This is not a bundle of independently checkable requirements. Correctly, the rule leaves the separate 'direct conjunction' / 'brand of' clarity requirement and the (b)(2) prominence requirement out of scope.
- Determinism 'judgment' is right: although a type-size ratio is measurable, application turns on whether the proprietary name is 'featured' above or below the column, which presentation is the 'most prominent' benchmark, and whether the proprietary name's type is 'larger' than the column's running-text type — all impression/prominence judgments. The escalate-when clause correctly names exactly these ambiguities.
- Authority 'binding' is correct — this is codified regulation (21 CFR 202.1), not guidance. Locator 21 CFR 202.1(b)(1) is precise and matches where the quoted sentence sits.
- applies_when is justified and appropriately limited: §202.1 governs prescription-drug advertisements (promotional, prescription), and 'column of running text' with type-size comparison is inherently a print-layout concept, so the print limit is an inference from the provision's own terms rather than an invented restriction.
- Severity 'blocker' is defensible: absence of the established name in association with the proprietary name is a §502(n)-linked misbranding exposure, not a stylistic defect, and cannot be cured by disclaimer.
- Minor, non-blocking: the rule narrative says 'proprietary name' where the source says 'proprietary name or designation'; the check's locate step preserves 'or designation', so scope is not materially lost.

Nearby rules

US-NAME-007 US-NAME-008 US-NAME-010